A groundbreaking gene-editing strategy is raising hopes that future treatments for rare genetic disorders could become far more accessible, faster to develop, and significantly more affordable.

Published in Nature, the new method shifts away from the traditional approach of fixing each individual genetic mutation. Instead, researchers aim to correct an entire class of mutations using a single, universal strategy. 

Senior author Dr. David Liu, from the Broad Institute and Harvard University, explained to The New York Times that rather than repairing one mutation at a time, the goal is to create a “disease-agnostic” technique capable of helping many more patients, regardless of the exact error in their DNA.

This work is particularly significant because more than 7,000 rare genetic disorders collectively affect about 400 million people worldwide, even though each condition impacts relatively small numbers individually. 

Many of these disorders are caused by what are known as nonsense mutations. These mutations insert a premature “stop” signal into a gene, causing the cell to halt production of a needed protein midway. Without fully formed proteins, vital bodily functions break down, leading to severe and often life-limiting diseases.

To tackle this, Liu’s team engineered a special molecule called a suppressor tRNA. Its job is to help the cell ignore the faulty stop signal and continue producing the full protein. 

One independent expert, Fyodor Urnov of UC Berkeley, described the innovation with a vivid analogy: instead of building “a better mousetrap,” the researchers “invented a cat.”

Using a technique known as prime editing, the team inserted the suppressor tRNA into cells, replacing an unused natural tRNA. This new method has been named PERT, short for prime editing-mediated readthrough of premature termination codons. 

In laboratory testing, PERT performed impressively. It avoided unwanted genetic changes, showed no signs of toxicity, and successfully restored protein production in models of several serious diseases, including Batten disease, Tay-Sachs disease, cystic fibrosis, and Niemann-Pick disease type C1. 

A mouse model of Hurler syndrome also responded positively, with restored protein function reaching levels that could meaningfully ease symptoms.

Scientists believe this strategy could one day help thousands of people living with conditions driven by premature stop signals. For example, a significant share of patients with Duchenne muscular dystrophy and cystic fibrosis could benefit. 

Those with Stargardt disease or phenylketonuria may also see meaningful possibilities in the future, as these conditions often stem from the same kind of genetic glitch.

The greatest appeal of this approach is its scale. Instead of designing a custom therapy for each individual mutation within a disease, researchers could develop one treatment capable of addressing multiple variations. 

Genomic-editing expert Rodolphe Barrangou from North Carolina State University said the new method has tremendous potential to shift the field from personalized editing toward more generalized, widely applicable solutions.

Still, he cautioned that several years of testing will be required before the technique is ready for use in humans.

Delivering gene-editing tools to the right cells remains a major challenge, especially in complex organs like the brain and lungs.

Dr. Richard Lifton of Rockefeller University noted that figuring out how to reach all the relevant cells in the body is one of the biggest scientific obstacles. There are also financial barriers. 

Many genetic diseases are so rare that pharmaceutical companies often struggle to justify the high cost of developing mutation-specific treatments. A universal method like PERT could help bridge that gap.

However, experts warn that progress in gene editing must be approached with care. Recent events, including the death of a participant in a clinical trial by Intellia Therapeutics, underscore the need for extreme caution as these technologies advance. 

As Urnov put it, PERT represents “a fundamentally new kind of engine,” but before that engine can carry passengers, researchers must build the right kind of plane.

For now, scientists and patient communities are watching closely, encouraged by early results and hopeful that this new approach could open the door to safer, more scalable genetic treatments for millions of people worldwide.